Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cryptos Rise Amidst The Dollar's Retreat
-
$BTC: Legendary Investor Paul Tudor Jones Says He Has ‘Always’ Owned Some Bitcoin
-
Coinbase CEO Thinks Brazil and Argentina Should ‘Consider Moving to Bitcoin’
-
NIO Up 8% On Improved Quarterly Sales
-
Bitcoin Poised for Explosive Growth to $190,000 After Crossing the $30,000 Threshold, Analyst Says